A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

NCT03852251 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

338

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Adenocarcinoma
Advanced Solid Tumors
Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL: AK104
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

Akeso

Collaborators

[object Object]